GB-0895 NCT07276724 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 3

Clinical phase

Recruiting

Recruitment status

786

Planned enrollment

2028-12-01

Primary-completion proxy

Executive view

NCT07276724 evaluates GB-0895 in Severe asthma. The disclosed sponsor is Generate Biomedicines, Inc., the design is Interventional, and the geographic footprint is Greece, Netherlands, Latvia, Romania, Hungary, Czechia, United States, South Africa, Bulgaria, Portugal, Germany. The first listed primary endpoint is To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma., assessed over From Day 1 (randomization) to Week 52.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07276724 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Severe asthma landscape. Drug & Asset MCP drug_fetch was queried for GB-0895, while Company & Deal Intelligence MCP organization_fetch was queried for Generate Biomedicines, Inc..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07276724	GB-0895	Phase 3 / Recruiting	Generate Biomedicines, Inc.	Greece, Netherlands, Latvia, Romania, Hungary, Czechia, United States, South Africa, Bulgaria, Portugal, Germany	To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled as… From Day 1 (randomization) to Week 52	2028-12-01
NCT07363642	Tezepelumab	Phase 3 / Recruiting	AstraZeneca PLC	China	To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in… within 36 weeks after the first administration	2028-02-07
NCT07359846	GB-0895	Phase 3 / Recruiting	Generate Biomedicines, Inc.	Argentina, United States, Japan, Ukraine, United Kingdom, Spain, Belgium, Turkey, Italy, Slovakia, Serbia, France, Australia, Estonia	To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled as… From Day 1 (randomization) to Week 52	2029-01-01
NCT07343661	Mepolizumab	Phase 4 / Enrolling by invitation	Azienda Ospedaliero Universitaria di Cagliari	Italy	Saliva, sputum, and plasma proteomic profile of EGPA patients From the data to the enrollment until the end of the study, up to 52…	2026-10-17
NCT07013123	Tezepelumab	Phase 3 / Not yet recruiting	University Hospital of Montpellier	Geography not reported	Annualized total number of asthma exacerbations under acarizax/placebo treatment Between Day 0 and Month 18	2029-08-18

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07276724 is a Phase 3, recruiting study with 786 planned participants. Allocation is Randomized, masking is Triple, and the intervention model is Parallel Assignment.

The primary endpoint is “To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma.” over “From Day 1 (randomization) to Week 52.” The retrieved endpoint description is: The annual exacerbation rate is based on clinically significant (CS) exacerbations reported by the investigator in the electronic case (eCRF) over 52 weeks for subjects on GB-0895 as compared to placebo..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 786 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Severe asthma. These records do not establish direct evidence for NCT07276724 unless the registration number matches.

Tezepelumab in the Framework of Use in Special Situations Before Commercialization: T-ROSS, a Retrospective Real-world Study in Spain

Not Applicable; n=33; clinical remission = 13.8 % Source: https://pubmed.ncbi.nlm.nih.gov/42002456/

B32-32 Evolution in the Use of Biologics Among US Adults With Severe Asthma: Data From the CHRONICLE Study

Not Applicable; n=4366; Biologic initiation(From December 2021 to February 2025) = 31.1 % ; Biologic initiation(From December 2021 to February 2025) = 33.2 % Source: https://academic.oup.com/ajrccm/article/212/Supplement_1/aamag162.472/8679419

A36-12 The Asthma Treatment Paradox: High Steroids, Low Controllers, and Fewer Biologics

Not Applicable; n=740; Biologic therapy utilization = 11.3 % Source: https://academic.oup.com/ajrccm/article/212/Supplement_1/aamag162.339/8679805

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

No exact Drug & Asset MCP profile was returned for the protocol wording “GB-0895.” The report therefore avoids inferring modality, target or global development stage from the name alone.

No exact Company & Deal Intelligence profile was returned for Generate Biomedicines, Inc.. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether GB-0895 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07276724
Protocol source: https://clinicaltrials.gov/study/NCT07276724
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.

GB-0895 in Severe asthma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma. and 2028-12-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP